Genous

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Genous is an endothelial progenitor cell (EPC) capture technology manufactured by OrbusNeich that promotes the accelerated natural healing of the vessel wall after stent implantation. The pro-healing technology has an antibody surface coating that captures circulating CD34+ endothelial progenitor cells to the device, forming a functional endothelial layer over the stent to protect against thrombus and minimize restenosis.[1][2]

The Genous Stent is a bio-engineered coronary stent coated with immobilized anti-CD34 monoclonal antibodies specific to the Genous technology.[3][4]

The Combo Dual Therapy Stent is a coronary stent that combines Genous with an antiproliferative, biodegradable sirolimus drug elution. The Combo Stent was shown to be as effective as a paclitaxel-eluting stent in controlling Neointimal Hyperplasia.[5][6][7]

References[edit]

  1. ^ Bylander, Jessica (27 October 2008). "New Stents On The Block: Innovators Look Beyond Drug Coatings." The Gray Sheet.
  2. ^ "Novel stent promotes healing of vessel wall after implantation" Cardiology Today
  3. ^ Klomp M, Beijk MA, de Winter RJ (July 2009). "Genous™ endothelial progenitor cell-capturing stent system: a novel stent technology". Expert Review of Medical Devices. 6 (4): 365–375. doi:10.1586/erd.09.16. Retrieved 28 August 2012.
  4. ^ "Genous stent is a safe and effective option in STEMI patients" Cardiovascular News International
  5. ^ London, Susan (14 November 2011). "Bioengineered, Sirolimus-Eluting Stent Found ‘Safe,’ and ‘Effective.’" Cardiology News.
  6. ^ "Dual-Therapy Stenting: The Next Step in the Evolution of Stent Design" Cardiology Today: Intervention
  7. ^ "TCT: Combo Stent Comparable to Taxus" MedPage Today

External links[edit]